Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed/ refractory (R/R) Acute Myeloid Leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial

Thomas Cluzeau, Pierre Yves Dumas, Pau Montesinos, Gaia Ciolli, Céline Berthon, Felicetto Ferrara, Adriano Venditti, José Antonio Pérez-Simón, Maria Calbacho, Richard Noppeney, Monia Lunghi, Chiara Cattaneo, Fabrizio Pane, Francesco Lanza, Juan Miguel Bergua Burgues, Alessandro Isidori, Yngvar Floisand, Vinay Jain, Eunice Wang

Blood (2025) 146 (Supplement 1): 767.

https://doi.org/10.1182/blood-2025-767

Published: 2025

Journal Articles

Only young age and genetics retain prognostic value for 2-year relapse-free survival in AML

Wissam Mahrez, Céline Berthon, Laurene Fenwarth, Carine Hauspie, Nicolas Duployez, Claude Preudhomme, Magalie Joris, Jean Pierre Marolleau, Delphine Lebon

Blood (2025) 146 (Supplement 1): 3382.

https://doi.org/10.1182/blood-2025-3382

Published: 2025

Journal Articles

Comprehensive mutational profiling and clinical outcome of adults AML with NUP98 rearrangement

Blood (2025) 146 (Supplement 1): 7002.

https://doi.org/10.1182/blood-2025-7002

Published: 2025

Journal Articles

Secondary-type acute myeloid leukemia is associated with a higher risk of invasive fungal infection during intensive induction therapy. a correlative study on the ALFA 0702 trial.

Blood (2025) 146 (Supplement 1): 994.

https://doi.org/10.1182/blood-2025-994

Published: 2025

Journal Articles

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Sarah Bertoli, Niklas Landberg, Emilie Bérard, Camille Gondran, Laetitia Largeaud, Véronique De Mas, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Sylvain Garciaz, Ludovic Gabellier, Gabrielle Roth-Guepin, Corentin Orvain, Pierre Peterlin, Rudy Birsen, Magda Alexis, Martin Carre, Emmanuelle Tavernier, Marion Boissard Simonet, Chantal Himberlin, Marc Maynadié, Kamel Laribi, Cécile Moluçon-Chabrot, Amine Belhabri, Samy Chraibi, Quentin Cabrera, Delphine Lebon, Emmanuel Raffoux, Thomas Cluzeau, Jean-Baptiste Micol, Mathieu Leclerc, Céline Berthon, Herve Dombret, Gunnar Juliusson, Anna Robelius, Sören Lehmann, Martin Jädersten, Lovisa Wennström, Pau Montesinos, Carmen Botella, Juan Miguel Bergua Burgues, Raimundo Garcia, Josefina Serrano, Mariluz Amigo, Patricia Garcia Ramirez, Claudia Sossa, Juan Manuel Alonso-Dominguez, Hartmut Döhner, Konstanze Döhner, Daniela Späth, Michael Kühn, Claudia Lengerke, Hans-Jörg Tischler, Christoph Röllig, Leo Ruhnke, Christian Thiede, Andreas Burchert, Hubert Serve, Carsten Mueller-Tidow, Claudia Baldus, Jurjen Versluis, Peter Valk, Daniel Kristensen, Anne Stidsholt Roug, Jiri Mayer, Mika Kontro, Pia Ettala, Vladimir Lazarevic, Christian Recher

Blood (2025) 146 (Supplement 1): 991.

https://doi.org/10.1182/blood-2025-991

Published: 2025

Journal Articles

Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup

Blood (2025) 146 (Supplement 1): 37.

https://doi.org/10.1182/blood-2025-37

Published: 2025

Journal Articles

Blinatumomab consolidation in high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in adults: Final report of the graall-2014/b-QUEST study.

Blood (2025) 146 (Supplement 1): 643.

https://doi.org/10.1182/blood-2025-643

Published: 2025

Journal Articles

Clinical and biological correlates of blast-transformed chronic myelomonocytic leukemia (CMML): A multicenter study of 493 paired cases at chronic phase and at blast transformation

Blood (2025) 146 (Supplement 1): 2081.

https://doi.org/10.1182/blood-2025-2081

Published: 2025

Journal Articles

Real-life CD34+CD38- leukemic stem cell (LSC) flow quantification in adult AML at diagnosis independently predicts survival of intensively but not AZA-VEN treated patients: A study of prospective observational ALFA-PPP acute leukemia french association

Blood (2025) 146 (Supplement 1): 3483.

https://doi.org/10.1182/blood-2025-3483

Published: 2025

Journal Articles

Real-world patterns of treatment intensity and prognostic model performance in older AML: Insights from the french ALFA-PPP cohort

Blood (2025) 146 (Supplement 1): 454.

https://doi.org/10.1182/blood-2025-454

Published: 2025

Journal Articles

Real life treatments and outcomes of older patients aged more than 60 years with FLT3-mutated acute myeloid leukemia: Report from the multicentric french observational ALFA-PPP study

Blood (2025) 146 (Supplement 1): 449.

https://doi.org/10.1182/blood-2025-449

Published: 2025

Journal Articles

Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup

Blood (2024) 144 (Supplement 1): 227.

https://doi.org/10.1182/blood-2024-194060

Published: 2024

Journal Articles

Treatments and Outcomes of Adult Patients with AML in the Real-Life - First Report of the French Observational ALFA-PPP Study

Blood (2024) 144 (Supplement 1): 2424.

https://doi.org/10.1182/blood-2024-207226

Published: 2024

Journal Articles

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Blood (2024) 143 (23): 2363–2372.

https://doi.org/10.1182/blood.2023023502

Published: 2024

Includes: Supplemental data

Journal Articles

Tetraspanin CD81 Supports Cancer Stem Cell Function and Represents a Therapeutic Vulnerability in Acute Myeloid Leukemia

Fanny Gonzales, Pauline Peyrouze, Thomas Boyer, Soizic Guihard, Francois Sevrin, Djohana Laurent, Adriana Plesa, Adeline Barthelemy, Antonino Bongiovanni, Claude Preudhomme, Nicolas Duployez, Celine Berthon, Christophe Roumier, Meyling H Cheok

Blood (2023) 142 (Supplement 1): 168.

https://doi.org/10.1182/blood-2023-186957

Published: 2023

Journal Articles

Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Blood (2023) 142 (Supplement 1): 1471.

https://doi.org/10.1182/blood-2023-174446

Published: 2023

Journal Articles

Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report

Blood (2023) 142 (Supplement 1): 518.

https://doi.org/10.1182/blood-2023-179192

Published: 2023

Journal Articles

Mutational Profile and Dynamics of PPM1D -Mutant Clones in the Spectrum of Myeloid Disorders

Blood (2023) 142 (Supplement 1): 4064.

https://doi.org/10.1182/blood-2023-189428

Published: 2023

Journal Articles

Impact of Residence in an Agricultural Zone on AML Characteristics

Vincent Marmouset, Berengere Gruson, Veronique Harrivel, Céline Berthon, Nicolas Duployez, Claude Preudhomme, Jean Pierre Marolleau, Pierre Morel, Carine Hauspie, Stéphane Morisset, Delphine Lebon

Blood (2023) 142 (Supplement 1): 2842.

https://doi.org/10.1182/blood-2023-173171

Published: 2023

Journal Articles

Clonal Dynamics of FLT3 -ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin

Romane Joudinaud, Augustin Boudry, Laurène Fenwarth, Sandrine Geffroy, Mikaël Salson, Herve Dombret, Céline Berthon, Arnaud Pigneux, Delphine Lebon, Lamya Haddaoui, Raphael Itzykson, Christian Recher, Audrey Bidet, Eric Delabesse, Mathilde Hunault, Claude Preudhomme, Nicolas Duployez, Pierre-Yves Dumas

Blood (2023) 142 (Supplement 1): 976.

https://doi.org/10.1182/blood-2023-182018

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed/ refractory (R/R) Acute Myeloid Leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial

Only young age and genetics retain prognostic value for 2-year relapse-free survival in AML

Comprehensive mutational profiling and clinical outcome of adults AML with NUP98 rearrangement

Secondary-type acute myeloid leukemia is associated with a higher risk of invasive fungal infection during intensive induction therapy. a correlative study on the ALFA 0702 trial.

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup

Blinatumomab consolidation in high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in adults: Final report of the graall-2014/b-QUEST study.

Clinical and biological correlates of blast-transformed chronic myelomonocytic leukemia (CMML): A multicenter study of 493 paired cases at chronic phase and at blast transformation

Real-life CD34+CD38- leukemic stem cell (LSC) flow quantification in adult AML at diagnosis independently predicts survival of intensively but not AZA-VEN treated patients: A study of prospective observational ALFA-PPP acute leukemia french association

Real-world patterns of treatment intensity and prognostic model performance in older AML: Insights from the french ALFA-PPP cohort

Real life treatments and outcomes of older patients aged more than 60 years with FLT3-mutated acute myeloid leukemia: Report from the multicentric french observational ALFA-PPP study

Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup

Treatments and Outcomes of Adult Patients with AML in the Real-Life - First Report of the French Observational ALFA-PPP Study

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Tetraspanin CD81 Supports Cancer Stem Cell Function and Represents a Therapeutic Vulnerability in Acute Myeloid Leukemia

Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report

Mutational Profile and Dynamics of PPM1D -Mutant Clones in the Spectrum of Myeloid Disorders

Impact of Residence in an Agricultural Zone on AML Characteristics

Clonal Dynamics of FLT3 -ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only